Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study
Jason K. Sicklick(University of California San Diego), Razelle Kurzrock(Medical College of Wisconsin), Ryosuke Okamura(Kyoto University Hospital), Amy Krie(Amgen (United States)), Mina Nikanjam(UC San Diego Health System), Casey Williams(Creighton University), Rana R. McKay(University of California San Diego), Jessica Guido(UC San Diego Health System), Brian Leyland‐Jones(Avera Health), Scott M. Lippman(UC San Diego Health System), Sarah G Boles, Benjamin Solomon(Avera Health), Shumei Kato(Center for Personalized Cancer Treatment), Jeffrey S. Ross(Unknown), Paul T. Fanta(Center for Personalized Cancer Treatment), Michael E. Hahn(University of California San Diego), Pradip De(Avera Health), Hitendra Patel(UC San Diego Health System)
Cited by 91
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
Lung Cancer
|New England Journal of Medicine|2008|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k